脳出血治療の最新治験 微小脳出血:その意義と管理

書誌事項

タイトル別名
  • Cerebral microbleeds: clinical features and management

抄録

Cerebral microbleeds (CMBs) on gradient-echo T2* weighted MRI, which are characterized histologically by the presence of hemosiderin around small vessels, are now accepted as a manifestation of cerebral small vessel disease (SVD) pathologies, including hypertensive small vessel disease and cerebral amyloid angiopathy (CAA). CMBs are often detected in patients with stroke, Alzheimer's disease, and mild cognitive impairment. The pathological differences in MBs according to distribution is now well known, with MBs in deep regions considered to be associated with hypertensive arteriopathy, whereas strictly lobar MBs share risk factors with CAA.<br> Evidence suggests that CMBs should not be considered to be clinically "silent". When CMBs are detected in healthy adults, physicians should recognize that subclinical SVD might have begun in their brain. Chronic hypertension can affect HA-related CMBs, as well as CAA-related CMBs. Furthermore, both types of CMBs are risk factor for intracranial hemorrhage under the antithrombotic drug use. Thus, CMBs should be considered as "warning sign" for inappropriate blood pressure control and antithrombotic drug use.<br> It seems clear that CMBs should be an important component of future studies to investigate how SVD influence neurodegeneration via neurovascular units in elderly populations.<br>

収録刊行物

  • 臨床神経学

    臨床神経学 52 (11), 1106-1109, 2012

    日本神経学会

参考文献 (8)*注記

もっと見る

詳細情報 詳細情報について

  • CRID
    1390001205036063232
  • NII論文ID
    130004505074
  • DOI
    10.5692/clinicalneurol.52.1106
  • COI
    1:STN:280:DC%2BC3s7ns1yrsg%3D%3D
  • ISSN
    18820654
    0009918X
  • PubMed
    23196531
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • Crossref
    • PubMed
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ